Literature DB >> 29525249

Prevalence and Predictive Value of Microvascular Flow Abnormalities after Successful Contemporary Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction.

Sourabh Aggarwal1, Feng Xie1, Robin High1, Gregory Pavlides1, Thomas R Porter2.   

Abstract

BACKGROUND: Although microvascular flow abnormalities have been observed following epicardial recanalization in acute ST-segment elevation myocardial infarction (STEMI), the prevalence and severity of these abnormalities in the current era of rapid percutaneous coronary intervention (PCI) has not been evaluated. The objective of this study was to assess microvascular perfusion (MVP) following successful primary PCI in patients with STEMI and how it affects clinical outcome.
METHODS: In this single-center, retrospective study, 170 patients who successfully underwent emergent PCI for STEMI were assessed using real-time myocardial contrast echocardiography using a continuous infusion of intravenous commercial microbubbles (3% Definity). Three patterns of myocardial contrast replenishment were observed following intermittent high-mechanical index impulses: infarct zone replenishment within 4 sec (normal MVP), delays in contrast replenishment but normal plateau intensity (delayed MVP [dMVP]), and both delays in replenishment and reduced plateau intensity (microvascular obstruction [MVO]). Changes in left ventricular ejection fraction at 6 months and clinical event rate at 12 months (death, recurrent infarction, need for defibrillator placement, or heart failure admission) were compared.
RESULTS: Normal MVP was seen in 62 patients (36%), dMVP in 49 (29%), and MVO in 59 (35%). Left anterior descending coronary artery infarct location was the only parameter independently associated with dMVP or MVO, independent of age, cardiac risk factors, door-to-dilation time, pre-PCI Thrombolysis In Myocardial Infarction flow grade, and thrombus burden. A dMVP pattern had a similar reduction in left ventricular ejection fraction as MVO at hospital discharge but had recovery of left ventricular ejection fraction at 6 months and a greater than fourfold lower event rate than the MVO group (P < .001).
CONCLUSIONS: MVO and dMVP are frequently seen following contemporary successful PCI for STEMI, especially following left anterior descending coronary artery infarction. Despite a similar area at risk, a dMVP pattern has better functional recovery and clinical outcome than MVO.
Copyright © 2018 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Microvascular obstruction; Ultrasound

Mesh:

Year:  2018        PMID: 29525249     DOI: 10.1016/j.echo.2018.01.009

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  5 in total

Review 1.  Cardiovascular Sonothrombolysis.

Authors:  Thomas R Porter; Wilson Mathias
Journal:  Curr Cardiol Rep       Date:  2019-07-25       Impact factor: 2.931

2.  Usefulness of echocardiographic myocardial work in evaluating the microvascular perfusion in STEMI patients after revascularization.

Authors:  Wenying Jin; Lan Wang; Tiangang Zhu; Yuliang Ma; Chao Yu; Feng Zhang
Journal:  BMC Cardiovasc Disord       Date:  2022-05-13       Impact factor: 2.174

Review 3.  Assessment and Treatment for Coronary Microvascular Dysfunction by Contrast Enhanced Ultrasound.

Authors:  Junzhen Zhan; Longhe Zhong; Juefei Wu
Journal:  Front Cardiovasc Med       Date:  2022-06-20

Review 4.  Pathophysiologic Basis and Diagnostic Approaches for Ischemia With Non-obstructive Coronary Arteries: A Literature Review.

Authors:  Bingqi Fu; Xuebiao Wei; Yingwen Lin; Jiyan Chen; Danqing Yu
Journal:  Front Cardiovasc Med       Date:  2022-03-17

Review 5.  Heart failure after myocardial infarction: incidence and predictors.

Authors:  Dominik Jenča; Vojtěch Melenovský; Josef Stehlik; Vladimír Staněk; Jiří Kettner; Josef Kautzner; Věra Adámková; Peter Wohlfahrt
Journal:  ESC Heart Fail       Date:  2020-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.